AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19963099
Drug: Temsirolimus 175
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temsirolimus 175 mg for 3 weeks followed by 75 mg once weekly (175/75)
Trial: 19581539
Drug: Investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice therapy
Trial: 23286772
Drug: 7-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-valent pneumococcal conjugate vaccine
Trial: 11233898
Drug: Preemptive or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive or prophylactic lamivudine treatment (n=10)
Trial: 11233898
Drug: Salvage lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Salvage lamivudine treatment after hepatic dysfunction (n=6)
Trial: 11233898
Drug: Prophylactic lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prophylactic lamivudine treatment (n=3)
Trial: 9780618
Drug: Isosorbide‐5‐mononitrate (IS5MN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide‐5‐mononitrate (IS5MN) 20 mg bid (8.00 am and 3.00 pm) for 1 week (Group 1)
Trial: 9780618
Drug: Isosorbide‐5‐mononitrate (IS5MN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide‐5‐mononitrate (IS5MN) 40 mg bid (8.00 am and 8.00 pm) for 1 week (Group 2)
Trial: 7937663
Drug: multi‐modality therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multi‐modality therapy using tuberculin, oliphen plus prednisolone
Trial: 3348612
Drug: Cefoperazone (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoperazone (3 g every 12 h) as a single agent
Trial: 3348612
Drug: Sulbactam (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulbactam (1.5 g every 12 h) as a single agent
Trial: 3348612
Drug: Cefoperazone and
RxNorm normalized name: Cefoperazone and sulbactam only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoperazone and sulbactam combination (3/1.5 g)
Trial: 25920000
Drug: Low-dose alcohol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose alcohol (peak BrAC of 40mg/dL)
Trial: 25920000
Drug: Moderate-dose alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate-dose alcohol (peak BrAC of 65mg/dL)
Trial: 21977941
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate (FF) 400 mcg once daily in the evening
Trial: 21977941
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate (FF) 200 mcg twice daily
Trial: 21977941
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate (FF) 400 mcg once daily in the morning
Trial: 16530911
Drug: Homemade clove
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homemade clove gel
Trial: 16530911
Drug: Benzocaine 20%
RxNorm normalized name: BENZOCAINE 20% GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzocaine 20% gel
Trial: 11014949
Drug: Vasopressin antagonist
RxNorm normalized name: Vasopressin antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasopressin antagonist Atosiban (1‐deamino‐2‐D‐Tyr(OEt)‐4‐Thr‐8‐Orn‐oxytocin)
Trial: 1425870
Drug: Omeprazole (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (240 mg administered in three divided doses over 22 hours)
Trial: 1425870
Drug: Normochlorhydria (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normochlorhydria (no omeprazole treatment)
Trial: 4085165
Drug: Active pulsed
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active pulsed electromagnetic field therapy (PEMF)
Trial: 4085165
Drug: Inactive pulsed
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive pulsed electromagnetic field therapy (PEMF)
Trial: 10959738
Drug: Inactivated Polio
RxNorm normalized name: Inactivated polio vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated Polio Vaccine (IPV)
Trial: 30512100
Drug: RAS inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAS inhibitor prescription at hospital discharge
Trial: 30512100
Drug: No RAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No RAS inhibitor prescription
Trial: 30512100
Drug: RAS inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAS inhibitor prescription at hospital discharge (stratified by preserved LVEF)
Trial: 30512100
Drug: No RAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No RAS inhibitor prescription (stratified by preserved LVEF)
Trial: 30512100
Drug: RAS inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAS inhibitor prescription at hospital discharge (KCCQ score analysis)
Trial: 30512100
Drug: No RAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No RAS inhibitor prescription (KCCQ score analysis)
Trial: 22267715
Drug: Vero cell
RxNorm normalized name: Vero Cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vero cell culture-derived influenza vaccine
Trial: 19172131
Drug: Glutamine-enriched enteral
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine-enriched enteral nutrition (0.3 g x kg(‐1) x day(‐1))
Trial: 10591888
Drug: Flumazenil (1
RxNorm normalized name: Flumazenil (18-F)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (1 mg/70 kg)
Trial: 10591888
Drug: Caffeine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (300 mg/70 kg; active drug control)
Trial: 11097144
Drug: Scopolamine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine administration
Trial: 25738849
Drug: Histochemical markers
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histochemical markers after retinol treatment
Trial: 25738849
Drug: Histochemical markers
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histochemical markers after vehicle treatment
Trial: 19494683
Drug: Measures to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measures to help modify the biofilm (including ozone therapy and probiotics)
Trial: 19494683
Drug: Measures to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measures to increase enamel resistance to demineralization (including laser treatment of enamel)
Trial: 19494683
Drug: Novel 'hybrid'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel 'hybrid' technique for treatment of primary molar caries (Hall technique)
Trial: 9834808
Drug: PCA with
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA with intravenous piritramide (group P-PCA)
Trial: 9834808
Drug: Nurse-administered bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-administered bolus injections of piritramide (group P-Bolus)
Trial: 9834808
Drug: Nurse-administered bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-administered bolus injections of bupivacaine (group B-Bolus)
Trial: 23364953
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (TDF) 300 mg for 48 weeks followed by open-label TDF for an additional 192 weeks
Trial: 23364953
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil (ADV) 10 mg for 48 weeks followed by open-label TDF for an additional 192 weeks
Trial: 21295383
Drug: Safflower oil
RxNorm normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safflower oil (SAF) 8 g daily for 16 weeks
Trial: 21295383
Drug: Conjugated linoleic
RxNorm normalized name: CONJUGATED LINOLEIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated linoleic acid (CLA) 8 g daily for 16 weeks
Trial: 17713595
Drug: Follow-up study
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up study after 6 months, n = 25 (combined treatment and placebo)
Trial: 15887629
Drug: G 5.0
RxNorm normalized name: Glucose 5.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G 5.0 mg/M 400 mg
Trial: 15887629
Drug: G 2.5
RxNorm normalized name: Zomig 2.5mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G 2.5 mg/M 400 mg
Trial: 15887629
Drug: G 5.0
RxNorm normalized name: Glucose 5.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G 5.0 mg/M 400 mg and G 2.5 mg/M 400 mg
Trial: 10904994
Drug: Madden operation
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Madden operation + tamoxifen 20 mg OD
Trial: 10904994
Drug: Tumorectomy to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumorectomy to disease free margins + tamoxifen 20 mg OD
Trial: 9287060
Drug: Topical water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical water and systemic doxycycline, 100 mg for 2 weeks
Trial: 9287060
Drug: Topical 0.12%
RxNorm normalized name: betamethasone topical 0.12% topical foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.12% chlorhexidine (CHX) and systemic doxycycline, 100 mg for 2 weeks
Trial: 9287060
Drug: Topical povidone‐iodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical povidone‐iodine and systemic doxycycline, 100 mg for 2 weeks
Trial: 9287060
Drug: Topical 0.12%
RxNorm normalized name: betamethasone topical 0.12% topical foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.12% CHX and placebo
Trial: 9287060
Drug: Topical water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical water and placebo
Trial: 3607094
Drug: Minimal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal treatment program (transcutaneous electrical nerve stimulation)
Trial: 18756443
Drug: Early activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early activation (1-2 months post-implant use)
Trial: 18756443
Drug: Late activation
RxNorm normalized name: Very late activation beta chain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late activation (1 year post-implant use)
Trial: 18756443
Drug: Control (prior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (prior to initial implant activation)
Trial: 11916780
Drug: Almitrine infusion
RxNorm normalized name: almitrine
DrugBank: Almitrine (DB01430)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine infusion at a rate of 8 microg x kg(‐1) x min(‐1) (Group A)
Trial: 9699223
Drug: Bioprim tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioprim tablets (80 mg of trimethoprim/400 mg sulfamethoxazole)
Trial: 9699223
Drug: Bactrim tablets
DrugBank: Sulfamethoxazole (DB01015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bactrim tablets (80 mg of trimethoprim/400 mg sulfamethoxazole)
Trial: 7521788
Drug: 750 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg/m2 cyclophosphamide (CHOP)
Trial: 7521788
Drug: 1200 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg/m2 cyclophosphamide (CHOP)
Trial: 7521788
Drug: 1500 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg/m2 cyclophosphamide (CHOP)
Trial: 4139900
Drug: Modifications in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modifications in treatment planning
Trial: 11289747
Drug: Radiotherapy as
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy as part of breast-conserving treatment (BCT) for DCIS
Trial: 11289747
Drug: Breast-conserving treatment
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast-conserving treatment (BCT) for DCIS without specific mention of control
Trial: 8431342
Drug: Alfentanil 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 20 micrograms kg‐1 and propofol 2.5 mg kg‐1
Trial: 29671256
Drug: Routine exogenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine exogenous administration of estrogens
Trial: 28169916
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg E4
Trial: 14669843
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg estradiol valerate (E2V)
Trial: 28267365
Drug: 10, 20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10, 20, or 40 mg E4
Trial: 20214694
Drug: Outpatient (OP)
RxNorm normalized name: OP-145
DrugBank: OP-145 (DB05672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient (OP) treatment
Trial: 20214694
Drug: Inpatient (IP)
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient (IP) treatment
Trial: 15025759
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (NO) administered at a constant low dose for up to 6 days
Trial: 9142028
Drug: 900 mL
RxNorm normalized name: OXYGEN 900 mL in 1 L RESPIRATORY (INHALATION) GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mL of albumin 5%
Trial: 9142028
Drug: 900 mL
RxNorm normalized name: OXYGEN 900 mL in 1 L RESPIRATORY (INHALATION) GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mL of Ringer's solution
Trial: 9142028
Drug: 900 mL
RxNorm normalized name: OXYGEN 900 mL in 1 L RESPIRATORY (INHALATION) GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mL of Ringer's acetate solution
Trial: 9142028
Drug: 900 mL
RxNorm normalized name: OXYGEN 900 mL in 1 L RESPIRATORY (INHALATION) GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mL blood withdrawal
Trial: 8359178
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 10 mg cisapride regimen
Trial: 8359178
Drug: 1 x
RxNorm normalized name: Black Cohosh 1 X Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 20 mg cisapride regimen
Trial: 8359178
Drug: 1 x
RxNorm normalized name: Black Cohosh 1 X Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 10 mg cisapride regimen
Trial: 8359178
Drug: Plasma concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma concentrations of cisapride after 2 x 10 mg
Trial: 8359178
Drug: Cisapride plasma
RxNorm normalized name: Cisapride
DrugBank: Cisapride (DB00604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisapride plasma concentrations greater than 60 ng.ml‐1
Trial: 2820157
Drug: 240 g/die
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 g/die supplementary mackerel diet, no physical training
Trial: 2820157
Drug: Reducing diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reducing diet and a proportion of mackerels of 125 g/d, no physical training
Trial: 2820157
Drug: Reducing diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reducing diet and mackerel diet 125 g/d as well as daily swimming training (20 to 30 min)
Trial: 27798335
Drug: Multiple micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple micronutrient supplements (MMNs)
Trial: 27798335
Drug: Fe60F (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fe60F (60 mg Fe and 400 μg folic acid)
Trial: 27798335
Drug: Fe30F (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fe30F (30 mg Fe and 400 μg folic acid)
Trial: 25265895
Drug: DPI GSK961081
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: DPI GSK961081 400 µg + oral placebo
Trial: 25265895
Drug: DPI GSK961081
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: DPI GSK961081 1,200 µg + oral placebo
Trial: 25265895
Drug: DPI GSK961081
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: DPI GSK961081 400 µg + oral propranolol 80 mg
Trial: 25265895
Drug: DPI GSK961081
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: DPI GSK961081 1,200 µg + oral propranolol 80 mg
Trial: 25265895
Drug: DPI and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPI and oral placebo
Trial: 22858074
Drug: Fixed-dose combined
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combined isosorbide dinitrate/hydralazine (FDC I/H)
Trial: 14557961
Drug: Clarithromycin (500-1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (500-1000 mg), Ethambutol (25 mg/kg), Rifampin (600 mg) 3 times per week
Trial: 8990504
Drug: Pure nanocolloid
RxNorm normalized name: Dream Pure BB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pure nanocolloid gel
Trial: 1333899
Drug: Continuous intra-arterial
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous intra-arterial infusion of 5-FU and lentinan with intermittent epirubicin
Trial: 6379275
Drug: Acetylsalicylic Acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic Acid (ASS) 100 mg/day
Trial: 30220261
Drug: Present-Centered Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Present-Centered Therapy (PCT; 10 sessions over 8 weeks)
Trial: 26289619
Drug: Avenanthramides (AVA)
RxNorm normalized name: AVENANTHRAMIDES
DrugBank: Avenanthramides (DB14743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avenanthramides (AVA) supplementation (9.2 mg AVA per day)
Trial: 24645793
Drug: Control (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0.4 mg AVA per day)
Trial: 22002961
Drug: Gaboxadol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gaboxadol (15 mg for subjects <65 years and 10 mg for subjects ≥65 years)
Trial: 16446317
Drug: Cyclic schedule
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic schedule of ProMECE-CytaBOM chemotherapy (cyc-PC, 6 cycles)
Trial: 16446317
Drug: Modified version
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified version of ProMECE-CytaBOM chemotherapy (seq-PC)
Trial: 28327266
Drug: Xylitol (8g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol (8g per 200 mL milk once per day)
Trial: 28327266
Drug: Xylitol (4g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol (4g per 100 mL milk twice per day)
Trial: 28327266
Drug: Sorbitol (8g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbitol (8g per 200 mL milk once per day)
Trial: 28327266
Drug: Sorbitol (4g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbitol (4g per 100 mL milk twice per day)
Trial: 28327266
Drug: Sucrose (8g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (8g per 200 mL milk once per day)
Trial: 28327266
Drug: Xylitol (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol (twice per day)
Trial: 28327266
Drug: Sorbitol (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbitol (twice per day)
Trial: 19171274
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment alone (group 2)
Trial: 11788637
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg T enanthate
Trial: 11788637
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg T enanthate
Trial: 11719309
Drug: Modafinil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (200 mg/d for Week 1; 400 mg/d for Weeks 2 to 4)
Trial: 9387176
Drug: Pressure-ridge Molteno
RxNorm normalized name: BLUE RIDGE BLUEBERRY
DrugBank: Blueberry (DB10629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure-ridge Molteno implant
Trial: 9387176
Drug: Standard Molteno
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Molteno implant with suture ligation
Trial: 9387176
Drug: Suture-ligation implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suture-ligation implant group
Trial: 9387176
Drug: Pressure-ridge implant
RxNorm normalized name: BLUE RIDGE BLUEBERRY
DrugBank: Blueberry (DB10629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure-ridge implant group
Trial: 7935033
Drug: 0.6 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/day of conjugated equine oestrogen (CEE) cyclically + 5 mg of medroxy‐progesterone acetate (MPA) for last 12 days
Trial: 7935033
Drug: 50 micrograms/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 micrograms/day of transdermal oestradiol cyclically + 5 mg of medroxy‐progesterone acetate (MPA) for last 12 days
Trial: 7935033
Drug: 0.625 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg/day of CEE + 5 mg/day of MPA uninterruptedly